Acumen Pharmaceuticals, Inc.

NasdaqGS:ABOS Rapporto sulle azioni

Cap. di mercato: US$141.8m

Acumen Pharmaceuticals Gestione

Gestione criteri di controllo 2/4

Acumen Pharmaceuticals Il CEO è Dan O'Connell, nominato in Dec2014, e ha un mandato di 9.92 anni. la retribuzione annua totale è $ 3.93M, composta da 15.2% di stipendio e 84.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.042% delle azioni della società, per un valore di $ 60.15K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3 anni e 6.1 anni.

Informazioni chiave

Dan O'Connell

Amministratore delegato

US$3.9m

Compenso totale

Percentuale dello stipendio del CEO15.2%
Mandato del CEO9.9yrs
Proprietà del CEO0.04%
Durata media del management3yrs
Durata media del Consiglio di amministrazione6.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Aug 05
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 30

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Apr 21
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10
We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07
We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01
Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dan O'Connell rispetto agli utili di Acumen Pharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$82m

Jun 30 2024n/an/a

-US$65m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$598k

-US$52m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$570k

-US$43m

Sep 30 2022n/an/a

-US$38m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$83m

Dec 31 2021US$1mUS$525k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$92m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$336kUS$240k

-US$7m

Compensazione vs Mercato: La retribuzione totale di Dan ($USD 3.93M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 647.72K ).

Compensazione vs guadagni: La retribuzione di Dan è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Dan O'Connell (54 yo)

9.9yrs

Mandato

US$3,930,011

Compensazione

Mr. Daniel J. O’Connell, also known as Dan, MBA was a Key Advisor at Acidophil, LLC. He served as President until February 01, 2024 and serves as Chief Executive Officer of Acumen Pharmaceuticals, Inc. si...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Daniel O'Connell
CEO & Director9.9yrsUS$3.93m0.042%
$ 60.1k
Matt Zuga
CFO & Chief Business Officer3.5yrsUS$1.61m0.14%
$ 196.1k
Derek Meisner
Chief Legal Officer & Corporate Secretary2.2yrsUS$1.48m0%
$ 0
James Doherty
President & Chief Development Officerless than a yearNessun datoNessun dato
Grant Krafft
Co-Founder28.8yrsUS$42.00kNessun dato
Caleb Finch
Co-Founderno dataNessun datoNessun dato
William Klein
Co-Founderno dataNessun datoNessun dato
Russell Barton
Chief Operating Officer3.8yrsUS$223.68k0.16%
$ 228.6k
Kelly Carranza
Vice President1.3yrsNessun datoNessun dato
Alex Braun
VP & Head of Investor Relations2.2yrsNessun datoNessun dato
Robyn Moxon
Associate Director of Communications2.5yrsNessun datoNessun dato
Julie Bockenstette
Executive VP & Head of Human Resources3.8yrsNessun datoNessun dato

3.0yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di ABOS è considerato esperto (durata media dell'incarico 3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Daniel O'Connell
CEO & Director18.6yrsUS$3.93m0.042%
$ 60.1k
Michael Weiner
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Colin Masters
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Jeffrey Cummings
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Sean Stalfort
Independent Chairman of the Board6.1yrsUS$173.52k0.51%
$ 717.3k
Kimberlee Drapkin
Independent Director2.6yrsUS$152.27k0%
$ 0
Steven DeKosky
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Jeffrey L. Ives
Independent Director10.5yrsUS$141.02k0%
$ 0
Reisa Sperling
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Cynthia Lemere
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato
Laura Stoppel
Independent Director4yrsUS$147.52k0%
$ 0
Stephen Salloway
Member of Clinical & Scientific Advisory Boardno dataNessun datoNessun dato

6.1yrs

Durata media

64.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ABOS sono considerati esperti (durata media dell'incarico 6.1 anni).